These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 39083163)

  • 1. Comparison of Real-World On-Label Treatment Persistence in Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Tumor Necrosis Factor Inhibitors.
    Walsh JA; Lin I; Zhao R; Shiff NJ; Morrison L; Emond B; Yu LH; Schwartzbein S; Lefebvre P; Pilon D; Chakravarty SD; Mease P
    Drugs Real World Outcomes; 2024 Sep; 11(3):487-499. PubMed ID: 39083163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study.
    Ogdie A; Merola JF; Mease PJ; Ritchlin CT; Scher JU; Lafferty KP; Chan D; Chakravarty SD; Langholff W; Wang Y; Choi O; Krol Y; Gottlieb AB
    BMC Rheumatol; 2024 May; 8(1):20. PubMed ID: 38773563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis.
    Siebert S; Coates LC; Schett G; Raychaudhuri SP; Chen W; Gao S; Seridi L; Chakravarty SD; Shawi M; Lavie F; Sharaf M; Zimmermann M; Kollmeier AP; Xu XL; Rahman P; Mease PJ; Deodhar A
    Arthritis Rheumatol; 2024 Jun; 76(6):894-904. PubMed ID: 38253404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-Care and Societal Costs Associated with Non-Persistence with Subcutaneous TNF-α Inhibitors in the Treatment of Inflammatory Arthritis (IA): A Retrospective Observational Study.
    Dalén J; Chitkara A; Svedbom A; Olofsson T; Puenpatom A; Black CM; Qureshi ZP
    Adv Ther; 2022 Jun; 39(6):2468-2486. PubMed ID: 34751912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthcare-Related Costs Associated with Switching Subcutaneous Tumor Necrosis Factor-α Inhibitor in the Treatment of Inflammatory Arthritis: a Retrospective Study.
    Dalén J; Luttropp K; Svedbom A; Black CM; Kachroo S
    Adv Ther; 2020 Sep; 37(9):3746-3760. PubMed ID: 32647910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic Burden of Switching to Different Biologic Therapies Among Tumor Necrosis Factor Inhibitor-Experienced Patients with Psoriatic Arthritis.
    Song Y; Betts KA; Lu Y; Singh R; Clewell J; Griffith J
    Rheumatol Ther; 2019 Jun; 6(2):285-297. PubMed ID: 31055779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Patterns Among Patients with Psoriatic Arthritis Treated with a Biologic in the United States: Descriptive Analyses from an Administrative Claims Database.
    Walsh JA; Adejoro O; Chastek B; Palmer JB; Hur P
    J Manag Care Spec Pharm; 2018 Jul; 24(7):623-631. PubMed ID: 29952704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying Predictors of First-Line Subcutaneous TNF-Inhibitor Persistence in Patients with Inflammatory Arthritis: A Decision Tree Analysis by Indication.
    Dalén J; Svedbom A; Hernlund E; Olofsson T; Black CM
    Adv Ther; 2023 Oct; 40(10):4657-4674. PubMed ID: 37599341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study.
    Ritchlin CT; Deodhar A; Boehncke WH; Soriano ER; Kollmeier AP; Xu XL; Zazzetti F; Shawi M; Jiang Y; Sheng S; Helliwell PS
    ACR Open Rheumatol; 2023 Mar; 5(3):149-164. PubMed ID: 36762512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy.
    Wei W; Knapp K; Wang L; Chen CI; Craig GL; Ferguson K; Schwartzman S
    Adv Ther; 2017 Aug; 34(8):1936-1952. PubMed ID: 28674959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry.
    Harrold LR; Stolshek BS; Rebello S; Collier DH; Mutebi A; Wade SW; Malley W; Greenberg JD; Etzel CJ
    Clin Rheumatol; 2017 Apr; 36(4):895-901. PubMed ID: 28271234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Persistence and Adherence Among Patients With Psoriatic Arthritis Who Initiated Targeted Immune Modulators in the US: A Retrospective Cohort Study.
    Walsh JA; Cai Q; Lin I; Pericone CD; Chakravarty SD
    Adv Ther; 2021 May; 38(5):2353-2364. PubMed ID: 33759081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs.
    Murage MJ; Princic N; Park J; Malatestinic WN; Zhu B; Atiya B; Kern SA; Stenger KB; Sprabery AT; Ogdie A
    J Manag Care Spec Pharm; 2022 Feb; 28(2):206-217. PubMed ID: 35098751
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study.
    Schett G; Chen W; Gao S; Chakravarty SD; Shawi M; Lavie F; Zimmermann M; Sharaf M; Coates LC; Siebert S
    Arthritis Res Ther; 2023 Aug; 25(1):150. PubMed ID: 37587493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment Persistence in Patients Cycling on Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors in Inflammatory Arthritis: A Retrospective Study.
    Dalén J; Puenpatom A; Luttropp K; Svedbom A; Black CM
    Adv Ther; 2022 Jan; 39(1):244-255. PubMed ID: 34480294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry.
    Choquette D; Bessette L; Alemao E; Haraoui B; Postema R; Raynauld JP; Coupal L
    Arthritis Res Ther; 2019 Jun; 21(1):138. PubMed ID: 31171024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic Arthritis.
    Rahman P; Boehncke WH; Mease PJ; Gottlieb AB; McInnes IB; Shawi M; Wang Y; Sheng S; Kollmeier AP; Theander E; Yu J; Leibowitz E; Marrache AM; Coates LC
    J Rheumatol; 2023 Jun; 50(6):769-780. PubMed ID: 36642439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
    Mease PJ; Ogdie A; Tesser J; Shiff NJ; Lin I; Chakravarty SD; Kelleman M; Dodge R; McLean RR; Broadwell A; Kavanaugh A; Merola JF
    Rheumatol Ther; 2023 Dec; 10(6):1479-1501. PubMed ID: 37597159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced.
    Ritchlin CT; Helliwell PS; Boehncke WH; Soriano ER; Hsia EC; Kollmeier AP; Chakravarty SD; Zazzetti F; Subramanian RA; Xu XL; Zuraw QC; Sheng S; Jiang Y; Agarwal P; Zhou B; Zhuang Y; Shawi M; Karyekar CS; Deodhar A
    RMD Open; 2021 Feb; 7(1):. PubMed ID: 33568556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison.
    Warren RB; McInnes IB; Nash P; Grouin JM; Lyris N; Willems D; Taieb V; Eells J; Mease PJ
    Rheumatol Ther; 2024 Jun; 11(3):829-839. PubMed ID: 38488975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.